Benjamin Lebwohl1, Olof Stephansson2, Peter H R Green3, Jonas F Ludvigsson4. 1. Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. 2. Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden; Division of Obstetrics and Gynecology, Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden. 3. Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. 4. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro, Sweden; Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. Electronic address: jonasludvigsson@yahoo.com.
Abstract
BACKGROUND & AIMS: Studies have associated undiagnosed celiac disease with adverse outcomes of pregnancy. We investigated the association between persistent villous atrophy and outcomes of pregnancy in women with celiac disease. METHODS: We collected data on 337 women with celiac disease who gave birth (to 460 infants) within 5 years of a follow-up biopsy, from 28 pathology departments in Sweden. We compared birth outcomes from women whose follow-up biopsy showed persistent villous atrophy (Marsh score, 3; n = 142; 31% of study population) with those of women with mucosal recovery (n = 318; 69%). We used multivariable logistic regression (adjusted for maternal age, parity, country of birth, smoking, infant sex, and calendar year of birth) to evaluate the association between persistent villous atrophy and pregnancy outcomes. RESULTS: Intrauterine growth restriction occurred during 3.5% of pregnancies in women with persistent villous atrophy vs 3.8% of those with mucosal healing (adjusted odds ratio [OR], 0.61; 95% confidence interval [CI], 0.19-1.99). There was no significant association between persistent villous atrophy and low birth weight (OR, 0.98; 95% CI, 0.41-2.39), preterm birth (OR, 1.66; 95% CI, 0.72-3.83), or cesarean section (OR, 0.86; 95% CI, 0.51-1.46). CONCLUSIONS: Although undiagnosed celiac disease has been associated with adverse outcomes of pregnancy, we found no evidence from a nationwide population-based study that persistent villous atrophy, based on analysis of follow-up biopsies, increases risk compared with mucosal healing.
BACKGROUND & AIMS: Studies have associated undiagnosed celiac disease with adverse outcomes of pregnancy. We investigated the association between persistent villous atrophy and outcomes of pregnancy in women with celiac disease. METHODS: We collected data on 337 women with celiac disease who gave birth (to 460 infants) within 5 years of a follow-up biopsy, from 28 pathology departments in Sweden. We compared birth outcomes from women whose follow-up biopsy showed persistent villous atrophy (Marsh score, 3; n = 142; 31% of study population) with those of women with mucosal recovery (n = 318; 69%). We used multivariable logistic regression (adjusted for maternal age, parity, country of birth, smoking, infant sex, and calendar year of birth) to evaluate the association between persistent villous atrophy and pregnancy outcomes. RESULTS:Intrauterine growth restriction occurred during 3.5% of pregnancies in women with persistent villous atrophy vs 3.8% of those with mucosal healing (adjusted odds ratio [OR], 0.61; 95% confidence interval [CI], 0.19-1.99). There was no significant association between persistent villous atrophy and low birth weight (OR, 0.98; 95% CI, 0.41-2.39), preterm birth (OR, 1.66; 95% CI, 0.72-3.83), or cesarean section (OR, 0.86; 95% CI, 0.51-1.46). CONCLUSIONS: Although undiagnosed celiac disease has been associated with adverse outcomes of pregnancy, we found no evidence from a nationwide population-based study that persistent villous atrophy, based on analysis of follow-up biopsies, increases risk compared with mucosal healing.
Authors: A S Khashan; T B Henriksen; P B Mortensen; R McNamee; F P McCarthy; M G Pedersen; L C Kenny Journal: Hum Reprod Date: 2009-11-24 Impact factor: 6.918
Authors: A Lanzini; F Lanzarotto; V Villanacci; A Mora; S Bertolazzi; D Turini; G Carella; A Malagoli; G Ferrante; B M Cesana; C Ricci Journal: Aliment Pharmacol Ther Date: 2009-03-03 Impact factor: 8.171
Authors: Jonas F Ludvigsson; Lena Brandt; Scott M Montgomery; Fredrik Granath; Anders Ekbom Journal: BMC Gastroenterol Date: 2009-03-11 Impact factor: 3.067
Authors: Martin W Laass; Roma Schmitz; Holm H Uhlig; Klaus-Peter Zimmer; Michael Thamm; Sibylle Koletzko Journal: Dtsch Arztebl Int Date: 2015-08-17 Impact factor: 5.594
Authors: Zsolt Szakács; Péter Mátrai; Péter Hegyi; Imre Szabó; Áron Vincze; Márta Balaskó; Bernadett Mosdósi; Patrícia Sarlós; Mária Simon; Katalin Márta; Alexandra Mikó; Dániel Pécsi; Alexandra Demcsák; Judit Bajor Journal: PLoS One Date: 2017-11-02 Impact factor: 3.240
Authors: Zsolt Szakács; Noémi Gede; Zoltán Gyöngyi; Margit Solymár; Dezső Csupor; Bálint Erőss; Áron Vincze; Alexandra Mikó; Andrea Vasas; László Szapáry; Dalma Dobszai; Viktória Balikó; Roland Hágendorn; Péter Hegyi; Judit Bajor Journal: Front Physiol Date: 2019-11-19 Impact factor: 4.566